Zolmitriptan Tablet, Orally Disintegrating
Product Images NDC 46708-182

6 FDA label images from Alembic Pharmaceuticals Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Zolmitriptan (NDC 46708-182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

2.5 mg 6 Tablets (Zolmitriptan 25mg)

2.5 mg 6 Tablets (Zolmitriptan 25mg)
Packaging label for Zolmitriptan Orally Disintegrating Tablets, USP 2.5 mg by Alembic Pharmaceuticals Limited. The label shows a box containing 6 unit dose tablets (1 x 6) and prominently displays the product name and strength. The label includes the NDC number 46708-181-06 and indicates the product is for prescription use only.*
FDA Label Image

5 mg 3 Tablets (Zolmitriptan 5mg)

5 mg 3 Tablets (Zolmitriptan 5mg)
Packaging label for Zolmitriptan Orally Disintegrating Tablets, USP 5 mg, by Alembic Pharmaceuticals Limited. The label indicates the product contains 3 unit dose tablets (1 x 3), is Rx only, and includes the NDC code 46708-182-03. The design features green accents and a barcode on the side panel.*
FDA Label Image

Figure 1 (Zolmitriptan Figure1)

Figure 1 (Zolmitriptan Figure1)
A line graph depicting the estimated probability of response over time from initial dose for Zolmitriptan tablets at 1 mg, 2.5 mg, 5 mg strengths, and placebo. The x-axis represents time from initial dose (0 to 4 hours), and the y-axis indicates estimated probability of response (0% to 100%). Zolmitriptan shows increasing response probabilities over time, with higher doses generally achieving greater response compared to placebo.*
FDA Label Image

Figure 2 (Zolmitriptan Figure2)

Figure 2 (Zolmitriptan Figure2)
A line graph showing the estimated probability of medication rescue over 24 hours from the initial dose, comparing placebo and three doses (1 mg, 2.5 mg, and 5 mg) of a medication. The x-axis represents time in hours, and the y-axis shows the probability percentage, illustrating the differences in rescue medication probability among the doses and placebo.*
FDA Label Image

Figure 3 (Zolmitriptan Figure3)

Figure 3 (Zolmitriptan Figure3)
A line chart comparing the estimated probability of response over time from initial dose between Zolmitriptan Orally Disintegrating Tablets 2.5 mg and placebo. The x-axis shows time in hours up to 2 hours, and the y-axis shows the probability of response as a percentage up to 100%. The chart indicates a higher response probability for the Zolmitriptan group compared to placebo over time.*
FDA Label Image

Figure 4 (Zolmitriptan Figure4)

Figure 4 (Zolmitriptan Figure4)
A line graph comparing the estimated probability of remediation or rescue over 24 hours from initial doses between placebo and Zolmitriptan Orally Disintegrating Tablets 2.5 mg. The x-axis shows time in hours, and the y-axis shows the probability percentage, with placebo showing a rapid increase early and plateauing near 85%, while Zolmitriptan increases more gradually to about 58%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.